Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

269
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
269
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

210
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
210
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

253
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
253
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

150
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
150

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural requirements of blood factors binding to soluble hexon trimers with implications for adenovirus cell targeting and immune evasion.

PLoS pathogens·2026
Same author

A Coronary Anatomy-Guided Myocardial Infarction Strategy for Optimizing Survival and Ventricular Tachycardia Inducibility in a Porcine Model.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Multicatheter Comparison of Very High-Power Short-Duration Radiofrequency Ablation Lesions.

Journal of cardiovascular electrophysiology·2026
Same author

Immune shielding of viral vectors via capsid engineering with genetically encoded zwitterionic peptides.

Molecular therapy. Advances·2026
Same author

Esophageal heating characteristics of very high-power short duration radiofrequency ablation in a myocardial phantom model.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2026
Same author

Transvenous microwave aorticorenal ganglion ablation improves renal denervation outcomes.

Journal of hypertension·2026

Related Experiment Video

Updated: Dec 23, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.0K

Improving Molecular Therapy in the Kidney.

Jeffrey D Rubin1, Michael A Barry2,3,4

  • 1Virology and Gene Therapy Graduate Program, Mayo Clinic, Rochester, MN, USA.

Molecular Diagnosis & Therapy
|April 24, 2020
PubMed
Summary

Gene therapy for genetic kidney diseases faces delivery challenges due to the glomerulus. Novel injection techniques and vector retargeting show promise for advancing kidney gene therapy.

More Related Videos

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.8K
Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

8.0K

Related Experiment Videos

Last Updated: Dec 23, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.0K
Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.8K
Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

8.0K

Area of Science:

  • Nephrology
  • Genetics
  • Molecular Biology

Background:

  • Approximately 80 genes are linked to genetic kidney diseases.
  • Gene therapy development for kidney disease lags behind other organs like the liver, muscles, and eyes.
  • Inefficient gene delivery to kidney cells via the bloodstream, due to glomerular filtration, is a major hurdle.

Purpose of the Study:

  • To review recent advances in gene delivery techniques for the kidney.
  • To explore how genetic knowledge can accelerate kidney gene therapy development.
  • To bridge the gap between genetic kidney disease knowledge and therapeutic applications.

Main Methods:

  • Review of novel gene delivery techniques in mouse models (e.g., retrograde ureter, renal vein, subcapsular injections).
  • Discussion of vector retargeting strategies for specific kidney cell targeting.
  • Analysis of existing genetic mouse models and gene therapy vectors.

Main Results:

  • Novel injection methods improve direct gene delivery to the kidney, bypassing glomerular filtration.
  • Vector retargeting offers a promising, yet underutilized, approach for kidney-specific gene delivery.
  • Progress in gene delivery is crucial for utilizing genetic insights in kidney disease treatment.

Conclusions:

  • Recent innovations in gene delivery show significant potential for treating genetic kidney diseases.
  • Combining advanced delivery methods with kidney genetics knowledge can accelerate the development of gene therapies.
  • Overcoming delivery barriers is key to translating genetic discoveries into clinical kidney disease treatments.